Literature DB >> 9765225

Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells.

H Takai1, M Kanematsu, K Yano, E Tsuda, K Higashio, K Ikeda, K Watanabe, Y Yamada.   

Abstract

Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) is a recently identified cytokine that belongs to the tumor necrosis factor receptor superfamily and regulates bone mass by inhibiting osteoclastic bone resorption. The present study was undertaken to determine whether OPG/OCIF is produced in bone microenvironment and how the expression is regulated. A transcript for OPG/OCIF at 3.1 kilobases was detected in bone marrow stromal cells (ST2 and MC3T3-G2/PA6) as well as in osteoblastic cells (MC3T3-E1). Transforming growth factor-beta1 (TGF-beta1) markedly increased the steady-state level of OPG/OCIF mRNA in a dose-dependent manner, while TGF-beta1 suppressed the mRNA expression of tumor necrosis factor-related activation-induced cytokine (TRANCE)/receptor activator of NF-kappaB ligand (RANKL), a positive regulator of osteoclastogenesis to which OPG/OCIF binds. The effect of TGF-beta1 on the expression of OPG/OCIF mRNA was transient, with a peak level at 3-6 h. The up-regulation of OPG/OCIF mRNA by TGF-beta1 in ST2 cells did not require de novo protein synthesis and involved both a transcriptional and a post-transcriptional mechanism. Western blot analysis and an enzyme-linked immunosorbent assay revealed that TGF-beta1 significantly increased the secretion of OPG/OCIF protein by ST2 cells at 6-24 h. In murine bone marrow cultures, TGF-beta1 markedly inhibited the formation of tartrate-resistant acid phosphatase-positive multinucleated osteoclast-like cells in the presence of 1,25-dihydroxyvitamin D3, whose effect was significantly reversed by a neutralizing antibody against OPG/OCIF. These results suggest that TGF-beta1 negatively regulates osteoclastogenesis, at least in part, through the induction of OPG/OCIF by bone marrow stromal cells and that the balance between OPG/OCIF and TRANCE/RANKL in local environment may be an important determinant of osteoclastic bone resorption.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765225     DOI: 10.1074/jbc.273.42.27091

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  RANK is essential for osteoclast and lymph node development.

Authors:  W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

Review 3.  Genetic disorders of the skeleton: a developmental approach.

Authors:  Uwe Kornak; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2003-07-31       Impact factor: 11.025

Review 4.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

5.  B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.

Authors:  Yan Li; Gianluca Toraldo; Aimin Li; Xiaoying Yang; Hongying Zhang; Wei-Ping Qian; M Neale Weitzmann
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

6.  Response of a preosteoblastic cell line to cyclic tensile stress conditioning and growth factors for bone tissue engineering.

Authors:  Eunna Chung; Marissa Nichole Rylander
Journal:  Tissue Eng Part A       Date:  2011-11-08       Impact factor: 3.845

7.  Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Authors:  Kirsten Q T Nguyen; Ping Olesen; Thomas Ledet; Lars Melholt Rasmussen
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

Review 8.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

9.  Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells.

Authors:  Tomoko Okada; Shingo Akikusa; Hiroaki Okuno; Masato Kodaka
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.

Authors:  Penny E Reid; Nicola J Brown; Ingunn Holen
Journal:  Mol Cancer       Date:  2009-07-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.